| Dr Berthie Marie Labissiere, DPM | |
|
7603 Georgia Ave Nw, Ste 100, Washington, DC 20012-1630 | |
| (202) 882-9682 | |
| (202) 882-4983 |
| Full Name | Dr Berthie Marie Labissiere |
|---|---|
| Gender | Female |
| Speciality | Podiatry |
| Experience | 28 Years |
| Location | 7603 Georgia Ave Nw, Washington, District Of Columbia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1821181223 | NPI | - | NPPES |
| 017138200 | Medicaid | DC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213E00000X | Podiatrist | PO582 (District Of Columbia) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Metropolitian Podiatry Assoc Pllc | 3577620681 | 2 |
News Archive
OSI Pharmaceuticals, Inc. today announced that the U.S. Patent & Trademark Office (PTO) has granted reissue patent RE41,065, replacing Tarceva's® (erlotinib) composition of matter patent (formerly No.5,747,498). The Company had applied for the reissue patent in February 2008, and on September 17, 2009 the Company had announced that the PTO had issued a "Notice of Allowance" accepting the Company's application to correct certain errors relating to the claiming of compounds, other than Tarceva, which had fallen outside of the scope of the main claim of the patent.
Social inequalities such as inadequate education, a lack of human rights, poverty and poor housing negatively can impact global health conditions, according to a report released Thursday by the World Health Organization's Commission on the Social Determinants of Health, Toronto's Globe and Mail reports.
On January 11, 2010, U.S. Consumer Product Safety Commission Chairman Inez Tenenbaum issued a statement at the APEC Toy Safety Initiative Dialogue in Hong Kong, China, warning manufacturers against the use of cadmium, antimony and barium in lieu of lead in children's products.
QR Pharma, Inc., a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment and Alzheimer's disease and the Medical University of South Carolina (MUSC) announced today that they received a Small Business Innovation Research (SBIR) phase I grant in the amount of $220,000 to study Posiphen® and its metabolites in cell culture and in transgenic Alzheimer mice.
› Verified 6 days ago
| Provider Name | Metropolitian Podiatry Assoc Pllc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1174616585 PECOS PAC ID: 3577620681 Enrollment ID: O20090317000291 |
News Archive
OSI Pharmaceuticals, Inc. today announced that the U.S. Patent & Trademark Office (PTO) has granted reissue patent RE41,065, replacing Tarceva's® (erlotinib) composition of matter patent (formerly No.5,747,498). The Company had applied for the reissue patent in February 2008, and on September 17, 2009 the Company had announced that the PTO had issued a "Notice of Allowance" accepting the Company's application to correct certain errors relating to the claiming of compounds, other than Tarceva, which had fallen outside of the scope of the main claim of the patent.
Social inequalities such as inadequate education, a lack of human rights, poverty and poor housing negatively can impact global health conditions, according to a report released Thursday by the World Health Organization's Commission on the Social Determinants of Health, Toronto's Globe and Mail reports.
On January 11, 2010, U.S. Consumer Product Safety Commission Chairman Inez Tenenbaum issued a statement at the APEC Toy Safety Initiative Dialogue in Hong Kong, China, warning manufacturers against the use of cadmium, antimony and barium in lieu of lead in children's products.
QR Pharma, Inc., a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment and Alzheimer's disease and the Medical University of South Carolina (MUSC) announced today that they received a Small Business Innovation Research (SBIR) phase I grant in the amount of $220,000 to study Posiphen® and its metabolites in cell culture and in transgenic Alzheimer mice.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Berthie Marie Labissiere, DPM 7603 Georgia Ave Nw, Ste 100, Washington, DC 20012-1630 Ph: (202) 882-9682 | Dr Berthie Marie Labissiere, DPM 7603 Georgia Ave Nw, Ste 100, Washington, DC 20012-1630 Ph: (202) 882-9682 |
News Archive
OSI Pharmaceuticals, Inc. today announced that the U.S. Patent & Trademark Office (PTO) has granted reissue patent RE41,065, replacing Tarceva's® (erlotinib) composition of matter patent (formerly No.5,747,498). The Company had applied for the reissue patent in February 2008, and on September 17, 2009 the Company had announced that the PTO had issued a "Notice of Allowance" accepting the Company's application to correct certain errors relating to the claiming of compounds, other than Tarceva, which had fallen outside of the scope of the main claim of the patent.
Social inequalities such as inadequate education, a lack of human rights, poverty and poor housing negatively can impact global health conditions, according to a report released Thursday by the World Health Organization's Commission on the Social Determinants of Health, Toronto's Globe and Mail reports.
On January 11, 2010, U.S. Consumer Product Safety Commission Chairman Inez Tenenbaum issued a statement at the APEC Toy Safety Initiative Dialogue in Hong Kong, China, warning manufacturers against the use of cadmium, antimony and barium in lieu of lead in children's products.
QR Pharma, Inc., a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment and Alzheimer's disease and the Medical University of South Carolina (MUSC) announced today that they received a Small Business Innovation Research (SBIR) phase I grant in the amount of $220,000 to study Posiphen® and its metabolites in cell culture and in transgenic Alzheimer mice.
› Verified 6 days ago
Dr. Arnold S. Ravick, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1145 19th Street, N.w., Suite 409, Washington, DC 20036 Phone: 202-223-0500 Fax: 202-296-2531 | |
Dr. Andrew Lewis Carver, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 1040 17th Street Nw, Washington, DC 20036 Phone: 202-296-2424 Fax: 202-318-8197 | |
Foot And Ankle Wellness Center Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 1160 Varnum St Ne Ste 200, Washington, DC 20017 Phone: 202-635-8306 | |
Michael Sean Stempel, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 2150 Pennsylvania Ave Nw, Dept. Of Medicine, Washington, DC 20037 Phone: 202-741-3333 | |
Dr. Harold Bruce Glickman, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 5513 Connecticut Ave Nw, Suite 210, Washington, DC 20015 Phone: 202-833-9797 Fax: 202-833-9799 | |
Dr. Barbara Anita Clorey, PA-C Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1350 Connecticut Ave Nw Ste 1250, Washington, DC 20036 Phone: 202-627-1901 | |
Dr. Sheldon I. Laps Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 1234 19th St Nw, Suite 610, Washington, DC 20036 Phone: 202-223-9020 Fax: 202-728-0874 |